News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

R-Tech Ueno Receives FDA IND Approval for RU-101 (r-HSA) to Treat Severe Dry Eye



4/26/2013 10:10:16 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ: 4573): This is to announce that we have submitted IND(Note1) application to US Food and Drug Administration (FDA(Note2)) for clinical trials of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101(Note3)) which is being developed in our company, and we received an approval by FDA. This allows us to initiate Phase I/II clinical trials for RU-101 ophthalmic solution which is being developed for treatment of severe dry eye. We are currently developing RU-101 ophthalmic solution to treat severe dry eye for which no effective treatment has been established, and planning to perform Phase I/II clinical trials in United States for treatment of severe dry eye.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES